CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 20 enrolled
Drug / intervention
Zaleplondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03489304
NCT03489304Phase 2Completed
CompareCT.gov

A 6-week Open-Label Study of Treatment of Insomnia With Zaleplon in HIV Positive Patients With Comorbid Depression

University of Pennsylvania·interventional·Posted Apr 5, 2018·Updated Oct 16, 2018

In Brief

A Phase 2 clinical trial evaluating Zaleplon for HIV/AIDS and Clinical Depression. Completed, enrolled 20 participants across 1 site.

Detailed Summary

In HIV positive patients with sleep onset insomnia and receiving pharmacologic treatment for comorbid depression, the proposed study aims to evaluate the impact of zaleplon on sleep measures determined by insomnia severity index (ISI) and Epworth sleepiness scale (ESS).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV/AIDS, Clinical Depression
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedApr 5, 2018
Enrollment StartApr 3, 2014
Primary CompletionFeb 4, 2015
TodayJul 2, 2026
Enrollment to primary: 10 monthsPosted 8.2 years ago

Interventions

Zaleplondrug

non-benzodiazepine hypnotic agent